The nephrology landscape has undergone more structural change in five years than in the prior two decades. SGLT2 inhibitors have redefined the CKD standard of care. IgA Nephropathy has become the most competitive rare kidney disease approval landscape in the market. GLP-1 receptor agonists are emerging as an unexpected force in kidney protection, and across glomerular diseases – FSGS, C3G, membranous nephropathy, IC-MPGN – a generation of targeted therapies is moving through development simultaneously.

Spherix has tracked nephrology through this transition continuously, with the clinical depth to distinguish signal from noise in a category where the science and the commercial dynamics are both evolving fast. The Spherix nephrology-dedicated team brings deep clinical and commercial fluency across the full kidney disease landscape. Nephrologists are a smaller specialty population managing patients with significant comorbidity complexity, which makes prescriber access harder than it looks – the Spherix nephrology community is a rigorously screened group of practicing US nephrologists, continuously maintained across CKD, dialysis, rare glomerular disease, and the emerging GLP-1 landscape, giving clients a direct line into how the field is actually treating patients today, not how it treated them two years ago.